Epoetin Alfa Therapy for Anemia in Chronic Kidney Disease

Iron Status and Supplementation

The American College of Physicians recommends checking transferrin saturation ≥20% and serum ferritin ≥100 ng/mL before starting ESA therapy, as iron deficiency is a common cause of inadequate response to epoetin alfa 1
The National Kidney Foundation suggests that iron supplementation should be prioritized first in non-dialysis CKD patients with hemoglobin <110 g/L (11 g/dL) and ferritin <100 ng/mL or transferrin saturation <20% 3
Intravenous iron is more effective than oral iron in CKD patients, increasing hemoglobin by 7-10 g/L versus 4-7 g/L with oral supplementation, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 3

The American Journal of Kidney Diseases recommends evaluating for chronic blood loss through stool guaiac testing, as occult gastrointestinal bleeding is common and causes both anemia and iron depletion 2
The European Renal Association suggests checking vitamin B12 and folate levels, as deficiencies impair hemoglobin synthesis and can cause poor response to epoetin alfa 2
The American College of Cardiology recommends assessing for inflammatory conditions that may cause functional iron deficiency despite adequate ferritin levels 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend a target hemoglobin of 110-120 g/L (11-12 g/dL) in CKD patients, as hemoglobin below 110 g/L is associated with increased morbidity and mortality 1
The National Institute of Diabetes and Digestive and Kidney Diseases suggests avoiding overcorrection, as targeting hemoglobin >130 g/L increases cardiovascular mortality and stroke risk 1
The American Society of Nephrology recommends monitoring hemoglobin every 2-4 weeks during dose titration and adjusting the ESA dose accordingly 1

The European Renal Association advises against starting epoetin alfa without checking iron studies first, as this is the most common cause of treatment failure 3, 2, 1
The American Journal of Kidney Diseases suggests not assuming anemia is solely due to erythropoietin deficiency in CKD, as 25-37.5% have concurrent iron deficiency 2
The American College of Cardiology recommends not targeting hemoglobin >130 g/L, as this increases cardiovascular events without additional benefit 1